Cargando…
Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma
BACKGROUND & OBJECTIVE: It has been shown that the combined use of alcohol before radiofrequency ablation (RFA) helps to augment the therapeutic advantage of RFA. The present study was conducted to compare the outcome of treatment with RFA alone and RFA with alcohol as ablative technique in pati...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890593/ https://www.ncbi.nlm.nih.gov/pubmed/29578192 http://dx.doi.org/10.4103/ijmr.IJMR_1812_15 |
_version_ | 1783312892416753664 |
---|---|
author | Kalra, Naveen Kang, Mandeep Duseja, Ajay K. Bhatia, Anmol Singh, Virendra Dhiman, Radha K. Rajwanshi, Arvind Chawla, Yogesh K. Khandelwal, Niranjan |
author_facet | Kalra, Naveen Kang, Mandeep Duseja, Ajay K. Bhatia, Anmol Singh, Virendra Dhiman, Radha K. Rajwanshi, Arvind Chawla, Yogesh K. Khandelwal, Niranjan |
author_sort | Kalra, Naveen |
collection | PubMed |
description | BACKGROUND & OBJECTIVE: It has been shown that the combined use of alcohol before radiofrequency ablation (RFA) helps to augment the therapeutic advantage of RFA. The present study was conducted to compare the outcome of treatment with RFA alone and RFA with alcohol as ablative technique in patients with small hepatocellular carcinomas (HCCs), who were not candidates for surgery. METHODS: Fifty patients with chronic liver disease and concurrent HCC were enrolled in this prospective study. The patients were treated with either RFA alone (n=25) or RFA combined with alcohol (n=25). Patient outcome was evaluated, and the tumour recurrence and survival of the patients were assessed in the two groups. RESULTS: The survival rates at six months in patients who completed at least six months of follow up were 84 and 80 per cent in patients treated with RFA alone and combination therapy, respectively. During the follow up period, 11 and four patients treated with RFA alone showed local and distant intrahepatic tumour recurrence, respectively. All local recurrences were at one to 18 months of the follow up period. The distant recurrences occurred at 6-36 months of the follow up period. During the follow up period, eight and six patients treated with combination therapy showed local and distant intrahepatic tumour recurrence, respectively. All local recurrences were at 1.5-15 months during the follow up period. The distant intrahepatic recurrences occurred at 6-72 months during the follow up period. INTERPRETATION & CONCLUSIONS: No significant difference was seen between the survival time of the patients treated with RFA alone and RFA with alcohol as well as in the local recurrences and distant intrahepatic recurrences in RFA compared to RFA and alcohol group patients. Combined use of RFA and alcohol did not improve the local tumour control and survival in patients with HCC compared to RFA alone. |
format | Online Article Text |
id | pubmed-5890593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-58905932018-04-19 Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma Kalra, Naveen Kang, Mandeep Duseja, Ajay K. Bhatia, Anmol Singh, Virendra Dhiman, Radha K. Rajwanshi, Arvind Chawla, Yogesh K. Khandelwal, Niranjan Indian J Med Res Original Article BACKGROUND & OBJECTIVE: It has been shown that the combined use of alcohol before radiofrequency ablation (RFA) helps to augment the therapeutic advantage of RFA. The present study was conducted to compare the outcome of treatment with RFA alone and RFA with alcohol as ablative technique in patients with small hepatocellular carcinomas (HCCs), who were not candidates for surgery. METHODS: Fifty patients with chronic liver disease and concurrent HCC were enrolled in this prospective study. The patients were treated with either RFA alone (n=25) or RFA combined with alcohol (n=25). Patient outcome was evaluated, and the tumour recurrence and survival of the patients were assessed in the two groups. RESULTS: The survival rates at six months in patients who completed at least six months of follow up were 84 and 80 per cent in patients treated with RFA alone and combination therapy, respectively. During the follow up period, 11 and four patients treated with RFA alone showed local and distant intrahepatic tumour recurrence, respectively. All local recurrences were at one to 18 months of the follow up period. The distant recurrences occurred at 6-36 months of the follow up period. During the follow up period, eight and six patients treated with combination therapy showed local and distant intrahepatic tumour recurrence, respectively. All local recurrences were at 1.5-15 months during the follow up period. The distant intrahepatic recurrences occurred at 6-72 months during the follow up period. INTERPRETATION & CONCLUSIONS: No significant difference was seen between the survival time of the patients treated with RFA alone and RFA with alcohol as well as in the local recurrences and distant intrahepatic recurrences in RFA compared to RFA and alcohol group patients. Combined use of RFA and alcohol did not improve the local tumour control and survival in patients with HCC compared to RFA alone. Medknow Publications & Media Pvt Ltd 2017-11 /pmc/articles/PMC5890593/ /pubmed/29578192 http://dx.doi.org/10.4103/ijmr.IJMR_1812_15 Text en Copyright: © 2017 Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Kalra, Naveen Kang, Mandeep Duseja, Ajay K. Bhatia, Anmol Singh, Virendra Dhiman, Radha K. Rajwanshi, Arvind Chawla, Yogesh K. Khandelwal, Niranjan Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma |
title | Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma |
title_full | Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma |
title_fullStr | Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma |
title_full_unstemmed | Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma |
title_short | Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma |
title_sort | comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890593/ https://www.ncbi.nlm.nih.gov/pubmed/29578192 http://dx.doi.org/10.4103/ijmr.IJMR_1812_15 |
work_keys_str_mv | AT kalranaveen comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT kangmandeep comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT dusejaajayk comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT bhatiaanmol comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT singhvirendra comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT dhimanradhak comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT rajwanshiarvind comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT chawlayogeshk comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma AT khandelwalniranjan comparisonofradiofrequencyablationaloneincombinationwithpercutaneousethanolinjectionformanagementofhepatocellularcarcinoma |